3rd Quarter - Report

VERTEX PHARMACEUTICALS INCORPORATED for VERTEX PHARMACEUTICALS INCORPORATED

Period 3rd Quarter 2011 Filed Oct 20, 2011 Signed by Samantha Ventimiglia, Senior Director, Government Affairs and Public Policy

Official filing
Firm
VERTEX PHARMACEUTICALS INCORPORATED
Client
VERTEX PHARMACEUTICALS INCORPORATED
Income
—
Expenses
$360,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Issues related to raising awareness of Hepatitis C (no specific bills); Viral Hepatitis and Liver Cancer Control and Prevention Act of 2010, all provisions; H.R. 2405 Pandemic and All-Hazards Preparedness Reauthorization Act of 2011, all provisions.

LobbyistCovered position, as disclosed
RACHEL WHITEFORD MACK —
RICHARD WAYNE OLSON —
SAMANTHA VENTIMIGLIA —

Contacted: SENATE; HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS); Centers For Disease Control & Prevention (CDC)

Bills named: H.R. 2405 (112th)

Budget/Appropriations BUD

FY 2012 Labor/HHS/Education Appropriations (H.R. 3070 and S. 1599), provisions related to viral hepatitis funding

LobbyistCovered position, as disclosed
RACHEL WHITEFORD MACK —
RICHARD WAYNE OLSON —
SAMANTHA VENTIMIGLIA —

Contacted: Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; Centers For Disease Control & Prevention (CDC); SENATE

Bills named: S. 1599 (112th), H.R. 3070 (112th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.